Advertisement
Document › Details
Polyplus-transfection S.A.. (12/17/22). "Press Release: Polyplus Acquires Xpress Biologics to Expand Plasmid DNA Offer". Strasbourg.
Polyplus, a leading solutions provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, has announced the completed acquisition of Xpress Biologics, a Belgian contract development and manufacturing organization (CDMO) specialized in the production of plasmid DNA and protein using microbial expression systems. The acquisition will strategically expand the Polyplus plasmid DNA engineering technology and services portfolio. In addition, it will strengthen Polyplus’ leading position focused on improving gene-therapy viral vector upstream process economics and quality.
“Over the past few years, Polyplus has been evolving with the goal of enhancing process economics in the advanced therapies sector. This acquisition combines the expertise of the Xpress Biologics team with our existing expertise in transfection within the Cell and Gene Therapy market,” CEO of Polyplus, Mario Philips commented. “We will combine our deep understanding of the gene-therapy viral vector manufacturing process with research and High-Quality grade plasmid production immediately and expect to have the capability to supply GMP grade plasmids around Q1 of 2023.”
Xpress Biologics contract development and manufacturing services will continue to be offered for Research, GLP, High Quality and GMP grade proteins and plasmids DNA for therapeutic, vaccine and diagnostic applications including mRNA and viral vector based advanced therapies, while being leveraged for large-scale production of Polyplus proprietary plasmid DNA. The proprietary plasmid DNA constructs engineered by Polyplus are developed to increase AAV production yields and quality in conjunction with innovative transfection offers.
“Xpress Biologics was built with a range of technologies and services, including optimized expression systems, for pre-clinical production and, as of 2023, clinical productions of new biologics” said Marc Daukandt, CEO at Xpress Biologics. “We see this acquisition as the next step forward in bringing our enabling technologies and products to the global market and help move advanced therapy discovery and commercialization forward.”
About Xpress Biologics
Xpress Biologics is a Belgian contract development and manufacturing organization (CDMO) specialized in the production of plasmid DNA and protein using bacteria and yeast expression systems. The company launched in 2014 with the mission of improving the value chain of drug development for Academics, Biotech and Pharma companies from R&D to manufacturing. Core applications for the technology and services include human and veterinary vaccines and biotherapeutics, as well as diagnostics.
About Polyplus
Polyplus is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services including bioproduction industry standard, PEIpro®. Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia. Learn more at https://bit.ly/3BsUwqY.
Media Contact Information:
Alengo Nyamay’antu, PhD
Marketing & Communication Team Leader - Polyplus
an@polyplus-transfection.com
Direct: +33 3 88 67 59 38
Record changed: 2024-01-06 |
Advertisement
More documents for Sartorius (Group)
- [1] Refeyn Ltd.. (10/2/23). "Press Release: Refeyn Announces Appointment of New CEO". Oxford....
- [2] Sartorius AG. (9/28/23). "Press Release: Sartorius Forms Partnership with Sparta Biodiscovery on Novel Nanoparticle Analysis Platform". Göttingen....
- [3] Sartorius AG. (8/17/23). "Press Release: Sartorius and Repligen Corporation Launch Integrated System with Biostat STR and XCell ATF for Upstream Process Intensification". Göttingen....
- [4] Helmholtz Zentrum München (Helmholtz Munich). (8/7/23). "Press Release: Life Science Factory to Open a New Location at Helmholtz Munich in 2024". Göttingen & Munich....
- [5] Sartorius AG. (8/3/23). "Press Release: Florian Funck Appointed CFO of Sartorius. New CFO to Take Over as of April 2024". Göttingen....
- [6] Life Science Factory Management GmbH. (7/24/23). "Pressemitteilung: Tatjana Kasper wird neue Geschäftsführerin". Göttingen....
- [7] Waters Corporation. (6/5/23). "Press Release: Waters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing". Milford, MA & Göttingen....
- [8] va-Q-tec AG. (4/26/23). "Press Release: Sartorius and va-Q-tec Announce a Long-term Partnership for the Joint Development of Innovative Transport Systems for the Biopharmaceutical Industry". Würzburg & Göttingen....
- [9] Sartorius. (3/31/23). "Press Release: Sartorius to Acquire Polyplus. France-based Polyplus Is a Provider of Innovative Upstream Technologies for Cell and Gene Therapies". Göttingen....
- [10] Life Science Valley Ventures Management GmbH. (2/13/23). "Press Release: New Fund for Promoting Life Science Start-ups in Lower Saxony". Göttingen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top